TCT 208: Multi-Organ Arterial Denervation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR IV Trial)
We Recommend
Disclosures
<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Study honoraria to institution, travel expenses, consulting fees (Relationships with industry are limited to reimbursement for clinical trials. Personal honoraria had not been paid) - 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, Celonova, Contego, Cor; Hangzhou Nuomao Medtech, Holistick Medical, Intershunt, Intervene, K2, Laminar, Lifetech, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics</li></ul>